Abstract: Provided herein is the identification and markers and genes associated with day-neutral autoflowering in plants and their use in selecting plants, including Cannabis plants, having autoflowering activity. The markers are useful for breeding autoflowering plants by obtaining nucleic acids, detecting one or more markers that indicate autoflowering activity, and establishing plant lines having such characteristics. Also provided are methods of editing plants to establish plant lines having autoflowering allelic variations.
Type:
Grant
Filed:
February 5, 2022
Date of Patent:
July 2, 2024
Assignee:
Phylos Bioscience, Inc.
Inventors:
Erica Bakker, Alisha Holloway, Kristen Waterman
Abstract: High-throughput methods for screening large populations of variant proteins are provided. The methods utilize large-scale arrays of microcapillaries, where each microcapillary comprises a solution containing a variant protein, an immobilized target molecule, and a reporter element. Immobilized target molecules may include any molecule of interest, including proteins, nucleic acids, carbohydrates, and other biomolecules. The association of a variant protein with a molecular target is assessed by measuring a signal from the reporter element. The contents of microcapillaries identified in the assays as containing variant proteins of interest can be isolated, and cells expressing the variant proteins of interest can be characterized. Also provided are systems for performing the disclosed screening methods.
Type:
Grant
Filed:
October 17, 2022
Date of Patent:
July 2, 2024
Assignee:
XCELLA Biosciences, Inc.
Inventors:
Jennifer R. Cochran, Bob Chen, Spencer Caleb Alford
Abstract: Described herein are compounds, pharmaceutical compositions and methods of using these compounds and pharmaceutical compositions for treating and/or preventing conditions such as amyotrophic lateral sclerosis. These compounds and pharmaceutical compositions are also useful as antivirals and antimicrobial agents.
Type:
Grant
Filed:
June 30, 2021
Date of Patent:
July 2, 2024
Assignee:
Prosetta Biosciences, Inc.
Inventors:
Kumarapandian Paulvannan, Dennis Solas, Anatoliy Kitaygorodskyy, Vishwanath R. Lingappa
Abstract: This invention relates to LOX enzyme-inhibiting compounds in accordance with Formula I or Formula II, or a pharmaceutically acceptable salt or hydrate thereof: and pharmaceutical compositions comprising the compounds. Such compounds and compositions can be useful in treating a variety of conditions, diseases, and disorders including, but not limited to, fibrotic disorders, proliferative disorders, cardiovascular disorders, acute and chronic inflammatory disorders, primary and metastatic cancer, pulmonary conditions, ocular diseases, and neurological and neuropsychiatric conditions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Type:
Grant
Filed:
October 28, 2022
Date of Patent:
June 25, 2024
Assignee:
Anovia Biosciences, Inc.
Inventors:
Michael Clare, Juan Du, Xiang Li, Ronggang Liu
Abstract: Described herein are compounds, pharmaceutical compositions and methods of using these compounds and pharmaceutical compositions for treating and/or preventing conditions such as, for example, those caused by any viral family causing respiratory viral disease, including specifically coronaviruses and influenza viruses.
Type:
Grant
Filed:
October 24, 2022
Date of Patent:
June 25, 2024
Assignee:
Prosetta Biosciences, Inc.
Inventors:
Vishwanath R. Lingappa, Kumarapandian Paulvannan
Abstract: Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human mitochondrial DNA (mtDNA). The disclosure further relates to the use of such recombinant meganucleases in combination with mitochondrial transit peptides in methods for producing genetically-modified eukaryotic cells, and to a population of genetically-modified eukaryotic cells wherein the mtDNA has been modified or edited.
Type:
Application
Filed:
April 22, 2022
Publication date:
June 20, 2024
Applicants:
Precision BioSciences, Inc., University of Miami
Inventors:
Carlos T. Moraes, James Jefferson Smith, Derek Jantz, Ginger H. Tomberlin, John Morris, Wendy Shoop
Abstract: Provided is a modified B-type natriuretic peptide (BNP) comprising a covalently attached polymer comprising amino acids, where the polymer inhibits degradation and/or elimination of the BNP in a subject, and where the modified BNP retains vasorelaxant activity. Nucleic acid molecules encoding the above-described modified BNP, as are vectors comprising the nucleic acid molecules, and cells comprising the vector. Methods of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition that can be treated with a natriuretic, diuretic or vasorelaxant is also provided. The methods comprise administering the above modified BNP to the subject. Further provided is method of preparing the above-described modified BNP.
Type:
Application
Filed:
November 14, 2023
Publication date:
June 20, 2024
Applicant:
Antlia BioScience, Inc.
Inventors:
Nigel Shankley, Brian Johnson, Sarkis Barret Kalindjian, Lars Friedrich
Abstract: Provided herein are programmable nucleases and methods of genome editing and detection of nucleic acids with said programmable nuclease. In some embodiments, the programmable nuclease is a programmable nickase.
Type:
Application
Filed:
February 22, 2024
Publication date:
June 13, 2024
Applicant:
Mammoth Biosciences, Inc.
Inventors:
Lucas Benjamin HARRINGTON, Janice Sha CHEN, Isaac Paterson WITTE
Abstract: The present invention relates in part to nucleic acids encoding proteins, therapeutics comprising nucleic acids encoding proteins, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described.
Abstract: The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
Type:
Grant
Filed:
April 26, 2023
Date of Patent:
June 11, 2024
Assignee:
Spruce Biosciences, Inc.
Inventors:
Alexis Howerton, Hal Gerber, Michael Huang
Abstract: The present disclosure encompasses engineered meganucleases that bind and cleave recognition sequences within a dystrophin gene. The present disclosure also encompasses methods of using such engineered meganucleases to make genetically modified cells. Further, the disclosure encompasses pharmaceutical compositions comprising engineered meganuclease proteins, or polynucleotides encoding engineered meganucleases of the disclosure, and the use of such compositions for the modification of a dystrophin gene in a subject, or for treatment of Duchenne Muscular Dystrophy.
Type:
Grant
Filed:
July 27, 2023
Date of Patent:
June 11, 2024
Assignee:
Precision BioSciences, Inc.
Inventors:
Gary Owens, Janel Lape, James Jefferson Smith, John Morris, Caitlin Turner, Whitney Lewis, Derek Jantz
Abstract: Method and apparatus for performing a plaque detection by using above focus and below focus images. Plaque is also detected by a method and apparatus using test and training data captured on an imaging system, building a new model for a specific virus/cell/protocol type to detect plaques, using the models in runtime systems to detect plaques and augmenting the models based on automatically calculated false positive and false negative counts and percentages taken from test runs and/or runtime data.
Abstract: The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 3 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized BCMA-CAR-T cells have specific killing activity against BCMA-positive tumor cells.
Abstract: The invention provides a method for genetic analysis in individuals that reveals both the genetic sequences and chromosomal copy number of targeted and specific genomic loci in a single assay. The present invention further provide methods for the sensitive and specific detection of target gene sequences and gene expression profiles.
Type:
Grant
Filed:
January 5, 2021
Date of Patent:
June 4, 2024
Assignee:
Resolution Bioscience, Inc.
Inventors:
Christopher K. Raymond, Christopher D. Armour, Lee P. Lim
Abstract: The disclosure relates to methods for colonizing a microbiome, by administering pharmaceutical compositions comprising a purified bacterial mixture to the subject. Also provided are methods for treating and/or preventing inflammatory bowel disease, methods for reducing the risk of inflammatory bowel disease and/or reducing the occurrence of inflammatory bowel disease in a subject by administering pharmaceutical compositions comprising a purified bacterial mixture to the subject. Also provided are methods for treating and/or preventing graft versus host disease in a subject by administering pharmaceutical compositions comprising a purified bacterial mixture to the subject.
Abstract: A clustered regularly interspaced short palindromic repeat (CRISPR)-associated complex for adaptive antiviral defence (Cascade); the Cascade protein complex comprising at least CRISPR-associated protein subunits Cas7, Cas5 and Cas6 which includes at least one subunit with an additional amino acid sequence possessing nucleic acid or chromatin modifying, visualising, transcription activating or transcription repressing activity. The Cascade complex with additional activity is combined with an RNA molecule to produce a ribonucleoprotein complex. The RNA molecule is selected to have substantial complementarity to a target sequence. Targeted ribonucleoproteins can be used as genetic engineering tools for precise cutting of nucleic acids in homologous recombination, non-homologous end joining, gene modification, gene integration, mutation repair or for their visualisation, transcriptional activation or repression.
Type:
Application
Filed:
January 25, 2024
Publication date:
May 30, 2024
Applicant:
Caribou Biosciences, Inc.
Inventors:
Stan Johan Josef Brouns, John van der Oast
Abstract: The present disclosure encompasses engineered meganucleases that bind and cleave recognition sequences within a dystrophin gene. The present disclosure also encompasses methods of using such engineered meganucleases to make genetically modified cells. Further, the disclosure encompasses pharmaceutical compositions comprising engineered meganuclease proteins, or polynucleotides encoding engineered meganucleases of the disclosure, and the use of such compositions for the modification of a dystrophin gene in a subject, or for treatment of Duchenne Muscular Dystrophy.
Type:
Grant
Filed:
July 27, 2023
Date of Patent:
May 28, 2024
Assignee:
Precision BioSciences, Inc.
Inventors:
Gary Owens, Janel Lape, James Jefferson Smith, John Morris, Caitlin Turner, Whitney Lewis, Derek Jantz
Abstract: An apparatus attaches to a microscope slide to form an enclosed fluidic chamber with input and output ports, where a tissue or cell sample on the slide can be processed using techniques such as immunohistochemical staining. Flow of reagents within the chamber can be laminar and highly uniform across the sample surface to achieve staining that is free of gradients. The sample can be imaged prior to, during, or after any given processing step. Methods for staining and imaging a sample can be implemented through one or more rounds of labeling, label removal or erasure and imaging. Samples can be imaged many times to achieve very high multiplexing levels. Samples can be placed on an imaging apparatus at various times and removed from the imaging apparatus for certain steps.
Type:
Grant
Filed:
June 15, 2020
Date of Patent:
May 28, 2024
Assignee:
Akoya Biosciences, Inc.
Inventors:
Julia Kennedy-Darling, Peter J. Miller, Peter Harvey
Abstract: Compounds and compositions that have a Protein Recognition Moiety bound to an electrophile for the selective covalent modification of targeted proteins to treat disorders mediated by the targeted protein are described.
Type:
Application
Filed:
September 5, 2023
Publication date:
May 23, 2024
Applicant:
Hyku Biosciences Inc.
Inventors:
Guillaume Barbe, Mark George Sauliner, William John Greenlee, Soumya Ray